Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has completed the conversion of 357.25 million unlisted shares into the same number of H shares, according to its Next Day Disclosure Return filed on 12 May 2026. The newly converted H shares are scheduled to begin trading on the Hong Kong Stock Exchange on 13 May 2026.

The transaction increases Xuanzhu Biopharma’s outstanding H shares to 517.95 million from 160.70 million, representing a 68.97% expansion in issued share capital. All previously unlisted shares have been fully converted, leaving no remaining unlisted shares on the company’s register.

The company confirmed that the conversion was duly authorized by its board and conducted in compliance with Hong Kong listing rules and all relevant regulatory requirements. No treasury share movements, share repurchases, or on-market sales were reported in the filing.